RxDoctor Payments Data

Nathan Fawbush, APRN

Family · Scott, ARNPI 1811401193

Payments from drug & device makers

$1,042in general payments, 2019–2025

Across 56 payments — averaging $18.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$180
  • Paratek Pharmaceuticals, Inc.$120
  • GSK$116
  • Lilly USA, LLC$88
  • Novo Nordisk$83
  • AbbVie$68
  • plus $387 from 16 others

What the payments were for

  • Food & beverage$1,042100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,042 in reported general payments places this provider in the 70th percentile of 2,103 family providers in Arkansas.

See all family providers in Arkansas

Medicare billing

Part B allowed, 2024
$59,107
Medicare patients
196
Services billed
2,702

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide135$176,408
EliquisApixaban108$71,882
Trelegy ElliptaFluticasone/Umeclidin/Vilanter79$62,158
OzempicSemaglutide43$47,804
UbrelvyUbrogepant24$27,909
JanuviaSitagliptin Phosphate21$23,717
QuliptaAtogepant18$21,324
JardianceEmpagliflozin27$16,971
LinzessLinaclotide17$14,396
NeurontinGabapentin15$12,768
Tresiba Flextouch U-100Insulin Degludec14$5,970
Gabapentin207$4,007
Albuterol Sulfate HfaAlbuterol Sulfate165$3,798
Omeprazole271$3,056
Potassium Chloride197$2,657

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$88$176,408135 claims
PfizerEliquis, Premarin$33$74,352120 claims
AbbVieUbrelvy, Qulipta, Linzess$68$63,62859 claims
GSKTrelegy Ellipta$116$62,15879 claims
Novo NordiskOzempic$83$47,80443 claims
MerckJanuvia$17$23,71721 claims
Boehringer IngelheimJardiance$13$16,97127 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,103 family providers in Arkansas.

Other family in Scott

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →